Kartos
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 6/3/2024
Pipeline by Phase
Therapeutic Focus
Clinical Trials (9)
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Started: 6/3/2024
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Started: 7/17/2023
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Started: 12/6/2021
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Started: 9/25/2019
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Started: 6/1/2023
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
Started: 12/27/2012
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Started: 12/19/2014
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Started: 4/1/2014